Shares of Zafgen, Inc. (NASDAQ:ZFGN) have received an average rating of “Hold” from the five analysts that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and one has issued a buy recommendation on the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $9.00.

A number of research analysts have recently issued reports on ZFGN shares. Zacks Investment Research downgraded Zafgen from a “buy” rating to a “hold” rating in a research note on Friday, September 1st. ValuEngine raised Zafgen from a “strong sell” rating to a “sell” rating in a research note on Thursday, July 6th.

In related news, insider Dennis D. Kim acquired 10,000 shares of the firm’s stock in a transaction on Tuesday, July 11th. The stock was purchased at an average cost of $3.39 per share, with a total value of $33,900.00. Following the acquisition, the insider now owns 21,443 shares of the company’s stock, valued at approximately $72,691.77. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 21.20% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the business. Parametric Portfolio Associates LLC increased its holdings in Zafgen by 55.8% during the 1st quarter. Parametric Portfolio Associates LLC now owns 28,832 shares of the biopharmaceutical company’s stock worth $134,000 after purchasing an additional 10,327 shares in the last quarter. Algert Global LLC bought a new stake in Zafgen during the 2nd quarter worth approximately $123,000. Nine Chapters Capital Management LLC bought a new stake in Zafgen during the 1st quarter worth approximately $170,000. Wells Fargo & Company MN increased its holdings in Zafgen by 1,290.3% during the 1st quarter. Wells Fargo & Company MN now owns 43,531 shares of the biopharmaceutical company’s stock worth $203,000 after purchasing an additional 40,400 shares in the last quarter. Finally, GSA Capital Partners LLP bought a new stake in Zafgen during the 2nd quarter worth approximately $259,000. 48.52% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This piece of content was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2017/09/06/zafgen-inc-zfgn-receives-average-recommendation-of-hold-from-analysts.html.

Zafgen (ZFGN) traded up 0.58% during midday trading on Wednesday, hitting $3.45. The stock had a trading volume of 82,711 shares. Zafgen has a 52 week low of $2.89 and a 52 week high of $5.46. The company’s 50 day moving average price is $3.47 and its 200-day moving average price is $4.01. The stock’s market capitalization is $94.82 million.

Zafgen (NASDAQ:ZFGN) last announced its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.03. During the same period last year, the company earned ($0.55) earnings per share. Equities analysts anticipate that Zafgen will post ($2.23) earnings per share for the current fiscal year.

About Zafgen

Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.

Receive News & Stock Ratings for Zafgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen Inc. and related stocks with our FREE daily email newsletter.